A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

Also called NCT04959305

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 245 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04959305
Other papers using this trial's data
  • Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension Journal of clinical hypertension (Greenwich, Conn.), 2023-05 DOI, PubMed 37095689, PMC10184484 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04959305. Randomized; double masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2022-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
Acronym
HM_APOLLO
Condition
Hypertension
Intervention (Drug)
HCP1803-3
Intervention (Drug)
RLD2003
Intervention (Drug)
RLD2004
Intervention (Drug)
RLD2005
Intervention (Drug)
HPP2003-3
Intervention (Drug)
HPP2005
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct04959305
Content hash
636470e181d82655c5ad1f8aa0ae90f6ee4fa1fd46ec56582539d13e2764a6c7